Cadrenal TherapeuticsCVKD
13F holders, Q1 2025 (March 31)13holders +4
7new positions
3sold out
$17.63avg. 13F price*
At the end of Q1 2025, 13 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, up 4 from Q4 2024. 7 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($805K), Geode Capital Management, LLC ($213K) and UBS Group AG ($149K).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $813K |
| Exits | 3 | $6K |
All 13F filers, Q4 2024 → Q1 2025: 54,903 shares bought and 444 shares sold, net +54,459 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Vanguard Group Inc. | 0.00% | New | 45,633 | $805K |
| Geode Capital Management, LLC | 0.00% | Add +14.5% | 12,086 | $213K |
| UBS Group AG | 0.00% | Add +288.8% | 8,445 | $149K |
| Osaic Holdings, Inc. | 0.00% | Add +200.0% | 1,500 | $26K |
| Morgan Stanley | 0.00% | Reduce -1.4% | 1,130 | $20K |
| Jones Financial Companies LLLP | 0.00% | New | 172 | $3K |
| JPMorgan Chase & Co. | 0.00% | New | 100 | $2K |
| Wells Fargo & Company | 0.00% | New | 100 | $2K |
| Physician Wealth Advisors, Inc. | 0.00% | New | 52 | $917 |
| Archer Investment Corp | 0.00% | No change | 35 | $617 |
| IFP Advisors, Inc | 0.00% | New | 30 | $529 |
| Bank of America Corp. | 0.00% | Add +10.0% | 11 | $194 |
| Frazier Financial Advisors, LLC | 0.00% | New | 10 | $177 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.